Company / Capital Expenditures
Ultragenyx Pharmaceutical Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$6.0M
FY2025
5-year range
$6.0M / $116.1M
FY2021-FY2025
Trend
-14.3%
vs FY2024
Sector context
#70 of 194
Health Care
What the data says
At $6M, Ultragenyx Pharmaceutical Inc.'s capital expenditures ranks #70 of 194 in the Health Care sector. Capital Expenditures has declined for 3 consecutive years, from $116M in FY2022 to $6M in FY2025.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of +8.0%.
Declined from $44M to $6M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -62.8%
- 5-Year CAGR
- +8.0%
- 10-Year CAGR
- -
Sector benchmark
#70 of 194 in Health CareTop 36% of 194This company $6.0M Sector average $117.5M
▼
-94.9% below sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of +8.0%, indicating consistent growth.
- In FY2025, capital expenditures decreased 14.3% year-over-year.
- Ranks #70 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.0M | -14.3% |
| FY2024 | $7.0M | -84.1% |
| FY2023 | $44.0M | -62.1% |
| FY2022 | $116.1M | +367.6% |
| FY2021 | $24.8M | +509.2% |
| FY2020 | $4.1M | +45.9% |
| FY2019 | $2.8M | -31.5% |
| FY2018 | $4.1M | -17.7% |
| FY2017 | $5.0M | +130.6% |
| FY2016 | $2.1M | -56.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026